Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710444 | 1.00 | NPSR1 (0.32) | NPSR1EGLN2TMPRSS2 | |
| SCHEMBL16710445 | 0.96 | NPSR1 (0.31) | NPSR1EGLN2TMPRSS2 | |
| SCHEMBL16708538 | 0.96 | NPSR1 (0.31) | NPSR1EGLN2TMPRSS2 | |
| SCHEMBL19101733 | 0.95 | NPSR1 (0.30) | NPSR1EGLN2 | |
| SCHEMBL23844102 | 0.93 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL19778894 | 0.92 | CYP3A4 (0.30) | — | |
| SCHEMBL26288320 | 0.92 | EGLN2 (0.33) | NPSR1EGLN2TMPRSS2 | |
| SCHEMBL16708541 | 0.90 | NPSR1 (0.30) | NPSR1EGLN2 | |
| SCHEMBL27436084 | 0.88 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL19101835 | 0.88 | TMPRSS2 (0.35) | NPSR1EGLN2TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644394-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4106876-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-114085243-B | Pyrrolo [1,2-f ] [1,2,4] triazines useful for the treatment of respiratory syncytial virus infection | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4106876-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-9701682-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9388208-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | ROSEMOUNT INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | NPSR1 508/4885EGLN2 1181/4885TMPRSS2 20/4885 |
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | NPSR1 3651/4885EGLN2 3668/4885TMPRSS2 738/4885 |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | NPSR1 508/4885EGLN2 1181/4885TMPRSS2 20/4885 |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | NPSR1 508/4885EGLN2 1181/4885TMPRSS2 20/4885 |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, SNRPA | NPSR1 1811/4885EGLN2 1885/4885TMPRSS2 826/4885 |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | NPSR1 508/4885EGLN2 1181/4885TMPRSS2 20/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | NPSR1 3651/4885EGLN2 3668/4885TMPRSS2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.